Treatment of an SCLC patient-derived xenograft (PDX) cell line with recombinant rSHH or viral infection with SMO-M2 accelerated cell proliferation in culture, whereas pharmacologic inhibition, genetic knockdown, or depletion of SHH/IHH by a blocking antibody inhibited tumor cell proliferation. This evidence concerns the gene IHH and neoplasm.